Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Reported Basic Consolidated EPS Of $-0.3995 For Period Ended 2015-06-30

0

The annual basic consolidated EPS for Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) for the period ended 2015-06-30 was $-0.3995. On quarterly basis, the basic consolidated EPS reading for the quarter ended 2015-06-30 was $-0.3995.

EPS from continuing operations

Coming to basic EPS from continuing operations, Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) reported $-0.3995 for the annual period ended 2015-06-30. Quarterly basic EPS from continuing operations for the three-month period ended 2015-06-30 stood at $-0.3995.

EPS contribution from parent

For the annual period ended 2015-06-30, Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) received basic EPS of $-0.3995 from its parent company. On quarterly basis, basic EPS contribution from the parent company for the period ended 2015-06-30 was $-0.3995.

Basic net EPS

For the annual period ended 2015-06-30, Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) reported basic net EPS of $-0.3783. On quarterly basis, the company’s basic net EPS for the three-month period ended 2015-06-30 stood at $-0.3783.

Consolidated diluted EPS

The annual consolidated diluted EPS reading for the period ended 2015-06-30 stood at $-0.3995. For the quarter ended 2015-06-30, consolidated diluted EPS was $-0.3995.

Basic diluted EPS

On annual basis, diluted EPS reading from continuing operation was $-0.3995 for the period ended 2015-06-30. Diluted EPS from continuing operations for the quarter ended 2015-06-30 was $-0.3995.

Net diluted EPS

Net diluted EPS reading for the annual period ended 2015-06-30 was $-0.3783. For the quarterly period ended 2015-06-30, net diluted EPS was $-0.3783.

Diluted EPS from parent

From the parent company, Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) received diluted EPS of $-0.3995 for the annual period ended 2015-06-30. On quarterly basis, diluted EPS contribution from the parent for the quarter ended 2015-06-30 was $-0.3995.

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) posted net basic EPS reading of $-0.42 for the annual period ended 2015-06-30. For the quarter, basic net EPS of $-0.42 was for the quarter ended 2015-06-30.

Net diluted EPS for Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) for the annual period ended 2015-06-30 was $-0.42. The company also reported net diluted EPS reading of $-0.42 for the quarter ended 2015-06-30.

The annual average basic shares outstanding for the period ended 2015-06-30 is 54.169 while for the quarter ended 2015-06-30 is 54.169.

The diluted shares outstanding for the fiscal year ended is 2015-06-30 is 54.169 while for the quarter ended 2015-06-30 is 54.169.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 23 times, 1 visits today)